Published in Mol Cell Biol on June 01, 2003
Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol (2011) 2.96
The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer (2013) 2.35
Genome-wide association and follow-up replication studies identified ADAMTS18 and TGFBR3 as bone mass candidate genes in different ethnic groups. Am J Hum Genet (2009) 2.14
TGF-β: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst (2014) 2.08
The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest (2006) 2.06
Less is more: unveiling the functional core of hematopoietic stem cells through knockout mice. Cell Stem Cell (2012) 1.71
Roles for the type III TGF-beta receptor in human cancer. Cell Signal (2010) 1.50
The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42. Proc Natl Acad Sci U S A (2009) 1.49
Modulation of noncanonical TGF-β signaling prevents cleft palate in Tgfbr2 mutant mice. J Clin Invest (2012) 1.37
TGFβ signaling and cardiovascular diseases. Int J Biol Sci (2012) 1.35
Cell biology of embryonic migration. Birth Defects Res C Embryo Today (2008) 1.14
Genetics of osteoporosis: accelerating pace in gene identification and validation. Hum Genet (2009) 1.14
Crucial role of the small GTPase ARF6 in hepatic cord formation during liver development. Mol Cell Biol (2006) 1.12
Transforming growth factor beta signaling in adult cardiovascular diseases and repair. Cell Tissue Res (2011) 1.10
Heparan sulfate proteoglycans: a GAGgle of skeletal-hematopoietic regulators. Dev Dyn (2008) 1.10
The mechanism of TGF-β signaling during palate development. Oral Dis (2011) 1.04
Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion. Cell Signal (2009) 1.04
The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2. Carcinogenesis (2009) 1.02
Co-ordinating Notch, BMP, and TGF-β signaling during heart valve development. Cell Mol Life Sci (2012) 1.01
Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta. Carcinogenesis (2008) 0.99
Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma. Oncogene (2010) 0.99
Erg is a crucial regulator of endocardial-mesenchymal transformation during cardiac valve morphogenesis. Development (2012) 0.98
Alternative splicing of TGF-betas and their high-affinity receptors T beta RI, T beta RII and T beta RIII (betaglycan) reveal new variants in human prostatic cells. BMC Genomics (2007) 0.96
The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myeloma cells. Mol Biol Cell (2011) 0.95
Betaglycan is required for the establishment of nephron endowment in the mouse. PLoS One (2011) 0.93
BMP-2 and TGFβ2 shared pathways regulate endocardial cell transformation. Cells Tissues Organs (2011) 0.93
The cytoplasmic domain of TGFβR3 through its interaction with the scaffolding protein, GIPC, directs epicardial cell behavior. Dev Biol (2011) 0.92
Sequencing of TGF-beta pathway genes in familial cases of intracranial aneurysm. Stroke (2009) 0.92
The transforming growth factor-beta type III receptor mediates distinct subcellular trafficking and downstream signaling of activin-like kinase (ALK)3 and ALK6 receptors. Mol Biol Cell (2009) 0.92
Inhibin-A antagonizes TGFbeta2 signaling by down-regulating cell surface expression of the TGFbeta coreceptor betaglycan. Mol Endocrinol (2010) 0.91
Inhibin at 90: from discovery to clinical application, a historical review. Endocr Rev (2014) 0.91
Targeting Stat3 and Smad7 to restore TGF-β cytostatic regulation of tumor cells in vitro and in vivo. Oncogene (2012) 0.90
Histology atlas of the developing mouse hepatobiliary system with emphasis on embryonic days 9.5-18.5. Toxicol Pathol (2010) 0.89
Betaglycan has two independent domains required for high affinity TGF-beta binding: proteolytic cleavage separates the domains and inactivates the neutralizing activity of the soluble receptor. Biochemistry (2009) 0.88
Transforming growth factor beta-1 decreases the yield of the second meiotic division of rat pachytene spermatocytes in vitro. Reprod Biol Endocrinol (2005) 0.86
Endogenous betaglycan is essential for high-potency inhibin antagonism in gonadotropes. Mol Endocrinol (2009) 0.85
Association of cystic fibrosis genetic modifiers with congenital bilateral absence of the vas deferens. Fertil Steril (2010) 0.85
TβRIII/β-arrestin2 regulates integrin α5β1 trafficking, function, and localization in epithelial cells. Oncogene (2012) 0.84
Vessel wall BAMBI contributes to hemostasis and thrombus stability. Blood (2014) 0.83
Lactoferrin causes IgA and IgG2b isotype switching through betaglycan binding and activation of canonical TGF-β signaling. Mucosal Immunol (2014) 0.83
SPSB1, a Novel Negative Regulator of the Transforming Growth Factor-β Signaling Pathway Targeting the Type II Receptor. J Biol Chem (2015) 0.82
ADAMTS3 activity is mandatory for embryonic lymphangiogenesis and regulates placental angiogenesis. Angiogenesis (2015) 0.81
Cell-type specific modulation of pituitary cells by activin, inhibin and follistatin. Mol Cell Endocrinol (2012) 0.81
The type III TGF-β receptor betaglycan transmembrane-cytoplasmic domain fragment is stable after ectodomain cleavage and is a substrate of the intramembrane protease γ-secretase. Biochim Biophys Acta (2010) 0.81
Changes in expression of proteoglycan core proteins and heparan sulfate enzymes in the developing and adult murine aorta. J Cardiovasc Transl Res (2011) 0.81
TGF-β signaling and its role in the regulation of hematopoietic stem cells. Syst Synth Biol (2015) 0.79
A Tale from TGF-β Superfamily for Thymus Ontogeny and Function. Front Immunol (2015) 0.79
Embryonic expression of the transforming growth factor beta ligand and receptor genes in chicken. Dev Dyn (2013) 0.78
The Local Control of the Pituitary by Activin Signaling and Modulation. Open Neuroendocrinol J (2011) 0.77
The type III TGFβ receptor regulates filopodia formation via a Cdc42-mediated IRSp53-N-WASP interaction in epithelial cells. Biochem J (2013) 0.77
Betaglycan (TβRIII) is expressed in the thymus and regulates T cell development by protecting thymocytes from apoptosis. PLoS One (2012) 0.77
Single live cell TGF-β signalling imaging: breast cancer cell motility and migration is driven by sub-populations of cells with dynamic TGF-β-Smad3 activity. Mol Cancer (2015) 0.76
TGF-β inhibitors stimulate red blood cell production by enhancing self-renewal of BFU-E erythroid progenitors. Blood (2016) 0.76
Functional role of TGF-β receptors during palatal fusion in vitro. Arch Oral Biol (2014) 0.76
Binding Properties of the Transforming Growth Factor-β Coreceptor Betaglycan: Proposed Mechanism for Potentiation of Receptor Complex Assembly and Signaling. Biochemistry (2016) 0.75
Altering the Proteoglycan State of Transforming Growth Factor β Type III Receptor (TβRIII)/Betaglycan Modulates Canonical Wnt/β-Catenin Signaling. J Biol Chem (2016) 0.75
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
TGF-beta signal transduction. Annu Rev Biochem (1998) 17.83
TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature (1997) 15.75
Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A (1993) 10.82
Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J (1998) 10.01
Controlling TGF-beta signaling. Genes Dev (2000) 8.13
Mechanism of activation of the TGF-beta receptor. Nature (1994) 8.10
TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development (1997) 6.31
Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest (1992) 4.49
Transforming growth factor-beta 3 is required for secondary palate fusion. Nat Genet (1995) 4.46
Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development (1995) 4.05
Regulatory phases of early liver development: paradigms of organogenesis. Nat Rev Genet (2002) 3.79
Betaglycan presents ligand to the TGF beta signaling receptor. Cell (1993) 3.48
Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A (1995) 3.25
Expression cloning and characterization of the TGF-beta type III receptor. Cell (1991) 2.89
Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Cell (1991) 2.73
Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart. Science (1999) 2.72
In situ hybridization analysis of TGF beta 3 RNA expression during mouse development: comparative studies with TGF beta 1 and beta 2. Development (1990) 2.53
Regulation of Smad activity. Cell (2000) 2.53
Maternal rescue of transforming growth factor-beta 1 null mice. Science (1994) 2.28
Peptide growth factors can provoke "fetal" contractile protein gene expression in rat cardiac myocytes. J Clin Invest (1990) 2.25
Double-outlet right ventricle and overriding tricuspid valve reflect disturbances of looping, myocardialization, endocardial cushion differentiation, and apoptosis in TGF-beta(2)-knockout mice. Circulation (2001) 2.23
Differential expression of TGF beta 1, beta 2 and beta 3 genes during mouse embryogenesis. Development (1991) 2.21
Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature (2000) 2.17
The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor Beta in fetal rat hepatocytes. Mol Cancer Res (2002) 2.01
Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J Biol Chem (1999) 1.94
TGFbeta2 and TGFbeta3 have separate and sequential activities during epithelial-mesenchymal cell transformation in the embryonic heart. Dev Biol (1999) 1.93
Distinct transforming growth factor-beta (TGF-beta) receptor subsets as determinants of cellular responsiveness to three TGF-beta isoforms. J Biol Chem (1990) 1.86
Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice. J Clin Invest (1997) 1.79
Homeotic transformation of the occipital bones of the skull by ectopic expression of a homeobox gene. Nature (1992) 1.74
Expression of activin subunits, activin receptors and follistatin in postimplantation mouse embryos suggests specific developmental functions for different activins. Development (1994) 1.74
Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc Natl Acad Sci U S A (1994) 1.60
Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites. J Cell Biol (1994) 1.59
RNA and protein localisations of TGF beta 2 in the early mouse embryo suggest an involvement in cardiac development. Development (1993) 1.48
Gain- and loss-of-function Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage. Immunity (2001) 1.41
Suppression of transforming growth factor-beta-induced apoptosis through a phosphatidylinositol 3-kinase/Akt-dependent pathway. Oncogene (1998) 1.36
Binding of transforming growth factor-beta to cell surface proteins varies with cell type. Mol Endocrinol (1989) 1.27
TGF beta in murine morphogenetic processes: the early embryo and cardiogenesis. Development (1990) 1.26
Inhibin is an antagonist of bone morphogenetic protein signaling. J Biol Chem (2002) 1.24
Apoptosis induced by transforming growth factor-beta in fetal hepatocyte primary cultures: involvement of reactive oxygen intermediates. J Biol Chem (1996) 1.22
Smad proteins and hepatocyte growth factor control parallel regulatory pathways that converge on beta1-integrin to promote normal liver development. Mol Cell Biol (2001) 1.20
Binding of two growth factor families to separate domains of the proteoglycan betaglycan. J Biol Chem (1992) 1.20
Regulation of transforming growth factor-beta signaling. Mol Cell Biol Res Commun (2001) 1.17
Stimulation and inhibition of cardiac myocyte proliferation in vitro. Mol Cell Biochem (1990) 1.16
Transforming growth factor-beta in the early mouse embryo: implications for the regulation of muscle formation and implantation. Dev Genet (1993) 1.15
A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. Cancer Res (1999) 1.13
Transforming growth factor-beta 2 is a transcriptional target for Akt/protein kinase B via forkhead transcription factor. J Biol Chem (2002) 1.13
Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-beta superfamily. Specialized binding regions for transforming growth factor-beta and inhibin A. J Biol Chem (2001) 1.13
Cooperative binding of transforming growth factor (TGF)-beta 2 to the types I and II TGF-beta receptors. J Biol Chem (1995) 1.06
Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor beta 2. J Biol Chem (1995) 1.05
Type III TGF-beta receptor-independent signalling of TGF-beta2 via TbetaRII-B, an alternatively spliced TGF-beta type II receptor. EMBO J (2001) 1.05
Betaglycan inhibits TGF-beta signaling by preventing type I-type II receptor complex formation. Glycosaminoglycan modifications alter betaglycan function. J Biol Chem (2001) 1.02
Expression of transforming growth factor beta type III receptor suppresses tumorigenicity of human breast cancer MDA-MB-231 cells. J Biol Chem (1997) 0.99
Betaglycan has multiple binding sites for transforming growth factor-beta 1. Biochem J (1996) 0.95
Differential responsiveness to autocrine and exogenous transforming growth factor (TGF) beta1 in cells with nonfunctional TGF-beta receptor type III. Cell Growth Differ (1999) 0.93
Subtypes of betaglycan and of type I and type II transforming growth factor-beta (TGF-beta) receptors with different affinities for TGF-beta 1 and TGF-beta 2 are exhibited by human placental trophoblast cells. J Cell Physiol (1992) 0.90
Expression of messenger ribonucleic acids encoding the inhibin/activin system during mid- and late-gestation rat embryogenesis. Endocrinology (1994) 0.88
Epidermal growth factor impairs the cytochrome C/caspase-3 apoptotic pathway induced by transforming growth factor beta in rat fetal hepatocytes via a phosphoinositide 3-kinase-dependent pathway. Hepatology (2000) 0.87
Plasmin cleaves betaglycan and releases a 60 kDa transforming growth factor-beta complex from the cell surface. Biochem J (1994) 0.87
A pivotal role for the transmembrane domain in transforming growth factor-beta receptor activation. J Biol Chem (1999) 0.85
Murine betaglycan primary structure, expression and glycosaminoglycan attachment sites. Biochim Biophys Acta (1998) 0.83
Concurrent and distinct transcription and translation of transforming growth factor-beta type I and type II receptors in rodent embryogenesis. Int J Dev Biol (1998) 0.83
Transforming growth factor beta modulates growth and differentiation of fetal hepatocytes in primary culture. J Cell Physiol (1995) 0.83
Extracellular domain of the transforming growth factor-beta receptor negatively regulates ligand-independent receptor activation. J Biol Chem (1999) 0.80
Hallmarks of cancer: the next generation. Cell (2011) 140.01
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 32.82
Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell (2004) 31.38
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature (2007) 21.53
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 18.53
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet (2008) 17.67
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20
Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell (2008) 14.80
A perspective on cancer cell metastasis. Science (2011) 13.31
Retracted A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell (2009) 10.51
Tumor metastasis: molecular insights and evolving paradigms. Cell (2011) 10.34
A progression puzzle. Nature (2002) 9.56
Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (2003) 8.07
Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A (2004) 7.96
Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res (2008) 7.91
Ras oncogenes: split personalities. Nat Rev Mol Cell Biol (2008) 7.91
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol (2010) 6.67
Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A (2010) 6.15
Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A (2011) 5.53
Modelling the molecular circuitry of cancer. Nat Rev Cancer (2002) 5.43
Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci U S A (2007) 5.24
Cancer stem cells: mirage or reality? Nat Med (2009) 5.20
The signals and pathways activating cellular senescence. Int J Biochem Cell Biol (2004) 5.00
Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell (2002) 4.92
Rules for making human tumor cells. N Engl J Med (2002) 4.84
Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol (2010) 4.80
Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell (2011) 4.79
Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol (2002) 4.77
Slug and Sox9 cooperatively determine the mammary stem cell state. Cell (2012) 4.77
The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet (2005) 4.70
Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle (2006) 4.67
Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell (2007) 4.30
Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med (2002) 4.28
Species- and cell type-specific requirements for cellular transformation. Cancer Cell (2004) 4.25
Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol (2012) 3.98
Exploring a new twist on tumor metastasis. Cancer Res (2006) 3.96
The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med (2013) 3.96
Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell (2008) 3.95
Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene (2002) 3.80
Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell (2008) 3.75
The Spemann organizer gene, Goosecoid, promotes tumor metastasis. Proc Natl Acad Sci U S A (2006) 3.64
Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell (2013) 3.61
Retracted Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell (2003) 3.56
High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res (2003) 3.48
Telomerase maintains telomere structure in normal human cells. Cell (2003) 3.29
Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer (2003) 3.23
Enrichment of a population of mammary gland cells that form mammospheres and have in vivo repopulating activity. Cancer Res (2007) 3.04
Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A (2010) 3.03
STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest (2008) 2.95
Telomeres: cancer to human aging. Annu Rev Cell Dev Biol (2006) 2.88
Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A (2002) 2.82
Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci U S A (2009) 2.75
Tumor-host interactions: a far-reaching relationship. J Clin Oncol (2010) 2.48
Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia (2010) 2.38
When cells get stressed: an integrative view of cellular senescence. J Clin Invest (2004) 2.37
A mouse model of human breast cancer metastasis to human bone. Cancer Res (2005) 2.24
Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol (2003) 2.24
Adaptation versus selection: the origins of metastatic behavior. Cancer Res (2007) 2.08
Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases. PLoS Pathog (2009) 2.07
Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. Nat Med (2005) 2.06
Micromanagers of malignancy: role of microRNAs in regulating metastasis. Trends Genet (2008) 2.03
Taking the study of cancer cell survival to a new dimension. Cell (2002) 2.03
Lyn tyrosine kinase: accentuating the positive and the negative. Immunity (2005) 2.01
Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest (2011) 1.96
Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J (2003) 1.93
Negative regulation of immunoglobulin E-dependent allergic responses by Lyn kinase. J Exp Med (2004) 1.91
Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell (2013) 1.86
Smad7 inhibits fibrotic effect of TGF-Beta on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol (2002) 1.86
IGF-2 is a mediator of prolactin-induced morphogenesis in the breast. Dev Cell (2002) 1.79
Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells? Int J Cancer (2011) 1.79
Erosion of the telomeric single-strand overhang at replicative senescence. Nat Genet (2003) 1.78
Cell plasticity and heterogeneity in cancer. Clin Chem (2012) 1.74
Retracted Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis. Genes Dev (2009) 1.74
MicroRNAs in malignant progression. Cell Cycle (2007) 1.74
Retracted Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis. Cancer Res (2010) 1.73
Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov (2012) 1.71
IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J Immunol (2008) 1.69
IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci U S A (2005) 1.66
Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res (2007) 1.66
MicroRNAs: Crucial multi-tasking components in the complex circuitry of tumor metastasis. Cell Cycle (2009) 1.63
Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol (2011) 1.51
miR-31: a crucial overseer of tumor metastasis and other emerging roles. Cell Cycle (2010) 1.51
Vascular endothelial growth factor D is dispensable for development of the lymphatic system. Mol Cell Biol (2005) 1.47
Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components. Proteomics (2013) 1.46
The outgrowth of micrometastases is enabled by the formation of filopodium-like protrusions. Cancer Discov (2012) 1.45
CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptor. J Biol Chem (2004) 1.45
Continuous elimination of oxidized nucleotides is necessary to prevent rapid onset of cellular senescence. Proc Natl Acad Sci U S A (2008) 1.41
Retracted Activation of miR-31 function in already-established metastases elicits metastatic regression. Genes Dev (2011) 1.40
SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res (2012) 1.39
An integrin-linked machinery of cytoskeletal regulation that enables experimental tumor initiation and metastatic colonization. Cancer Cell (2013) 1.36
Metastatic colonization: settlement, adaptation and propagation of tumor cells in a foreign tissue environment. Semin Cancer Biol (2010) 1.36
Role of TGF-beta signaling in extracellular matrix production under high glucose conditions. Kidney Int (2003) 1.29
Sustained activation of Lyn tyrosine kinase in vivo leads to autoimmunity. J Exp Med (2002) 1.29
Perturbed myelo/erythropoiesis in Lyn-deficient mice is similar to that in mice lacking the inhibitory phosphatases SHP-1 and SHIP-1. Blood (2004) 1.28
The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR. Oncogene (2004) 1.28
Roles for microRNAs in the regulation of cell adhesion molecules. J Cell Sci (2011) 1.25